Cognitive improvement during Tolcapone treatment in Parkinson's disease

Journal of Neural Transmission
M GaspariniG Meco

Abstract

The aim of this study was to evaluate the effects of Tolcapone, a reversible, selective inhibitor of catechol-O-methyltransferase, on the cognitive function of eight patients with advanced Parkinson's disease. They underwent neuropsychological and motor assessment at baseline and were re-evaluated after 6 months. During this period, they received Tolcapone three times daily, while the L-dopa dosage was progressively reduced. Significant improvements were observed in the attentional task, auditory verbal short-term memory, visuo-spatial recall, constructional praxia and motor symptoms. These data suggest that treatment with Tolcapone, in combination with L-dopa therapy, may determine a significant improvement in cognitive resources of patients with advanced Parkinson's disease.

References

Dec 1, 1992·Brain : a Journal of Neurology·A M OwenT W Robbins
Jan 1, 1992·Brain and Cognition·P ZimmermannC W Wallesch
Jan 1, 1992·Journal of Clinical Pathology·A J LoboA T Axon
Nov 1, 1991·Acta Neurologica Scandinavica·M H Hietanen
Jan 1, 1989·Neuropsychologia·C R ClarkL B Geffen
Jan 1, 1989·Movement Disorders : Official Journal of the Movement Disorder Society·E MohrT N Chase
Feb 1, 1989·Journal of Neurology, Neurosurgery, and Psychiatry·B PillonY Agid
Mar 1, 1989·Neurology·S J HuberE C Shuttleworth
Apr 1, 1988·Brain : a Journal of Neurology·A M GothamC D Marsden
Sep 1, 1987·Acta paediatrica Scandinavica·R A Surtees, D A Price
Sep 1, 1987·Journal of Neurology, Neurosurgery, and Psychiatry·E MohrT N Chase
Jun 25, 1982·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·T Shallice
May 1, 1984·Journal of Neurology, Neurosurgery, and Psychiatry·R G BrownM A Wyke
Jan 1, 1982·Brain and Cognition·F J PirozzoloM A Kuskowski
Jul 1, 1993·Neuropsychologia·A M OwenT W Robbins
Mar 1, 1996·Journal of Neurology, Neurosurgery, and Psychiatry·N FournetJ Pellat

❮ Previous
Next ❯

Citations

Sep 4, 2008·Psychopharmacology·Cherrie Galletly
Aug 24, 2012·Journal of Neural Transmission·Joseph A Schwartz, Kevin M Beaver
Sep 19, 2003·Current Psychiatry Reports·Thomas W McAllister, Lanier Summerall
Sep 10, 2004·Current Psychiatry Reports·Thomas W McAllisterC Harker Rhodes
Oct 1, 2008·Indian Journal of Clinical Biochemistry : IJCB·N GaurS Mishra
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·José A Apud, Daniel R Weinberger
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Catherine M Diaz-AsperTerry E Goldberg
Sep 19, 2006·Psychological Medicine·Jonathan Flint, Marcus R Munafò
Aug 2, 2007·Molecular Psychiatry·J A Gray, B L Roth
Oct 26, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·José A ApudDaniel R Weinberger
Apr 7, 2007·Schizophrenia Bulletin·Hywel J WilliamsMichael C O'Donovan
Jul 10, 2007·Schizophrenia Bulletin·John A Gray, Bryan L Roth
Jun 20, 2008·Schizophrenia Bulletin·Haraldur Magnus HaraldssonHannes Petursson
Oct 2, 2009·Gastroenterology Research and Practice·Kathleen ConnorBrad Butler
Apr 30, 2003·Proceedings of the National Academy of Sciences of the United States of America·Venkata S MattayDaniel R Weinberger
Sep 25, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Montse AlegretEduardo Tolosa
Dec 18, 2001·Biological Psychiatry·D R WeinbergerT E Goldberg
Aug 4, 2006·NeuroImage·Georg WintererDaniel R Weinberger
Jul 4, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·Lydia KrabbendamJim Van Os
Aug 12, 2006·Neuroscience and Biobehavioral Reviews·Lars BäckmanLars Farde
May 28, 2016·Neuroscience Research·Yukiori GotoEmanuel Jas
Sep 26, 2016·Clinical Pharmacokinetics·Thomas Müller, Paul Foley
Jun 20, 2014·Neuropsychologia·Yunsoo Park, Irwin D Waldman
Mar 4, 2014·Therapeutic Advances in Neurological Disorders·Thomas Müller, UNKNOWN TANIMOS Study Investigators
Aug 12, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert M BilderAnthony A Grace
Oct 21, 2004·The Cochrane Database of Systematic Reviews·K H O DeaneC E Clarke
Feb 24, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Amandine ValomonHans-Peter Landolt
Nov 21, 2019·Expert Opinion on Drug Discovery·Kalliopi MoschovouAntreas Afantitis
May 26, 2017·Expert Opinion on Drug Metabolism & Toxicology·Thomas Müller
May 4, 2004·CNS Spectrums·John A Bates, Anil K Malhotra
Feb 9, 2005·CNS Drugs·Gillian M Keating, Katherine A Lyseng-Williamson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.